Home/Investors/Atlas Venture

Atlas Venture

Biotech Investor · 9 portfolio companies

Portfolio

9

Combined Value

$14.7B

Focus Areas

19

Top Stage

Phase 1/2

Investment Focus

Neuromuscular Disorders Oncology Fibrosis Neuromuscular Diseases Rare Diseases Genetic Disorders Hematology Metabolic Diseases Liver Diseases Genetic Diseases Solid Tumors Anti-infective Cardiovascular Ophthalmology Dementia

Portfolio Companies

Company	Stage	Valuation	Focus
Scholar Rock Holding	Phase 3	$5.1B	Neuromuscular Disorders, Oncology
Dyne Therapeutics	Phase 1/2	$2.9B	Neuromuscular Diseases, Rare Diseases
Beam Therapeutics	Phase 1/2	$2.5B	Hematology, Oncology
Relay Therapeutics	Phase 2	$1.8B	Oncology, Genetic Diseases
Bicara Therapeutics	Phase 1/2	$1.2B	Oncology, Solid Tumors
Entrada Therapeutics	Phase 1/2	$433.0M	Neuromuscular Disorders, Metabolic Diseases
Bicycle Therapeutics	Phase 2	$301.8M	Oncology, Anti-infective
Foghorn Therapeutics	Phase 1	$293.5M	Oncology, Ophthalmology
Whitehawk Therapeutics	Phase 1/2	$169.4M	Oncology, Immuno-Oncology

Frequent Co-Investors

Arch Venture Partners2 shared Fidelity2 shared Third Rock Ventures2 shared BlackRock1 shared Public market investors1 shared EcoR1 Capital1 shared Other institutional and public shareholders1 shared Medicxi1 shared